President & CEO, Arecor and
Chair of EuropaBio's SME Platform
Tom Saylor is an experienced CEO with extensive experience building and managing entrepreneurial organizations. His experience includes fundraising, strategy development, in- and out-licensing, and acquisitions in Asia, Europe and the United States. He is currently CEO of Arecor Limited, a British company focused upon enabling the next generation of therapeutic proteins and vaccines through advanced formulation technologies. Previously, he was CEO of Sirus Limited, a drug targeting and delivery company based in Cambridge, England. Prior to joining Sirus, Tom was Chairman and founder of Lotus Healthcare Corporation, an Asian-based fully integrated pharmaceutical company. Tom built Lotus Healthcare from a small marketing group into a fully integrated producer and marketer of analgesics, cardiovascular and GI products with two GMP manufacturing sites and a sales staff of 100 representatives covering the top 35 cities of China. Tom was also Chief Executive Officer of Cell Systems Limited, a company focusing on medical applications of cryopreservation and algal biotechnology. Previously, Tom was Executive Vice President of a multi-billion dollar diversified industrial and financial group based in New York. He held a ministerial appointment and was a principal negotiator in the Tokyo Round of multilateral trade negotiations for the United States.
Tom is Chairman of the SME Platform, a member of the board of EuropaBio and the Executive Committee of the British North American Committee.
Tom holds an MBA from Harvard University undertook doctoral studies in molecular biology at the Max Planck Institute for Psychiatry in Munich and holds a degree in molecular biology from the Georgia Institute of Technology.
- Building a Sustainable Biotech Industry in Europe ( 220 KB)
The commercialization of biotechnology has lagged North America and faces increasing competition from Asia despite a very strong scientific base in Europe. While the number of companies in Europe is greater than the United States much fewer achieve their value potential. If Europe is going to benefit from advantages in science it will have to ensure the not only the encouragement of early stage companies but find better means to ensure a pathway where SME's can achieve sustainable value.
This requires a mixture of employing "best practices" which have been successful employed in member countries, SME-friendly measures employed by regulatory insitutions, and better use of grants and financial institutions in Europe to complement the private sector in achieving a sustainable biotech industry in Europe.